2 news items
Cogent Biosciences Announces Part 1b Data From SUMMIT Trial Evaluating Bezuclastinib In Patients With Nonadvanced Systemic Mastocytosis; 51% Week 12 Mean Change In Total Symptom Score, Including 70% Of Patients Achieving ≥50% Reduction In TSS At Week 12
COGT
22 Feb 24
for patients fighting systemic mastocytosis and gastrointestinal stromal tumors."Patient DemographicsSUMMIT is a randomized
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
COGT
22 Feb 24
." Patient DemographicsSUMMIT is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 clinical
- Prev
- 1
- Next